# Takeda Pharmaceutical (TAK) — News

TAK · NYSE · Stock

Canonical page: https://www.lighthorse.io/tickers/tak/news

## Recent headlines

- [Takeda: Orzeiful Oveprexton launches in Japan, China](https://www.ainvest.com/news/takeda-orzeiful-oveprexton-launches-japan-china-2610) — AInvest Wire, Oct 15, 2026
  Takeda Pharmaceuticals has announced the approval and launch of Orzeyful (oveporexton) in China and Japan for the treatment of narcolepsy type 1, marking a significant milestone in the company’s portfolio of neurological therapies. Orzeyful, a first-in-class orexin OX2 receptor agonist, was…
- [Iambic Therapeutics - Prices IPO of 9,375,000 shares at $16 per share](https://www.ainvest.com/news/iambic-therapeutics-prices-ipo-9-375-000-shares-16-share-2610) — AInvest Wire, Oct 14, 2026
  Iambic Therapeutics (IAM), a San Diego-based biotechnology firm leveraging artificial intelligence in drug discovery, has priced its initial public offering (IPO) at $16 per share, raising $150 million in gross proceeds. The offering includes 9.375 million shares on the Nasdaq Global Select Market,…
- [Iambic announces pricing of initial public offering](https://www.ainvest.com/news/iambic-announces-pricing-initial-public-offering-2610) — AInvest Wire, Oct 14, 2026
  Iambic Therapeutics Inc. has announced the pricing of its initial public offering (IPO), which it filed with the SEC . The San Diego-based biotechnology company, which leverages artificial intelligence for drug discovery, plans to list on Nasdaq . The IPO is expected to raise $159.4 million, with…
- [Takeda presents phase 2/3 Ignite study results of investigational subcutaneous TAK-881 in primary immunodeficiency disease (PID) at ESID 2026](https://www.ainvest.com/news/takeda-presents-phase-2-3-ignite-study-results-investigational-subcutaneous-tak-881-primary-immunodeficiency-disease-pid-esid-2026-2610) — AInvest Wire, Oct 14, 2026
- [Iambic Therapeutics - Ark investment and Duquesne family office indicate interest to purchase up to $60 mln in shares in IPO at IPO price](https://www.ainvest.com/news/iambic-therapeutics-ark-investment-duquesne-family-office-interest-purchase-60-mln-shares-ipo-ipo-price-2610) — AInvest Wire, Oct 8, 2026
  San Diego-based Iambic Therapeutics, a clinical-stage biotech firm leveraging AI for drug discovery, has filed for a $100 million IPO on the Nasdaq under the ticker "IAM". The company, backed by investors including Nvidia and the Qatar Investment Authority, is developing proprietary AI models with…

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).